Page 151 - CW E-Magazine (7-1-2025)

For Your Regular Requirement of
• Sodium Stearyl Fumarate Pharmaceuticals
• Sodium Tartrate Dihydrate
• Sorbic Acid
• Sorbitol EXPANDING PRESENCE
• Starch
• Stearic Acid Akums signs contract manufacturing deal worth
• Styrene Monomer
• Succinic Acid
• Sulphur €200-mn for European market
• Tannic acid
• Dl- Tartaric acid
• L- Tartaric acid Akums Drugs and Pharmaceuticals As part of the deal, Akums will
• Taurine
• Tertiary Butyl Hydroquinone Ltd., the New Delhi-based contract deve- receive an upfront payment of €100-mn
PLEASE CONTACT SUPPLIER: lopment and manufacturing organisation, (Rs. 880-crore) for product develop-
CHOICE ORGANOCHEM LLP has entered into a long-term agreement ment and site approval from European
G1/G2, Building No. B4, Ayodhya Kutir, with an undisclosed global pharma fi rm authorities.
Yashasvi Nagar, Balkum Road, Thane-400608,
Maharashtra, India. for manufacturing and supply of formula-
Phone: +91-40-23225550; +91-40-40202121 tions in the European market. Commenting on the development,
Mobile: +91-96183 33877
Email:cw@choiceorg.com Akums’ Managing Director Mr. Sanjeev
The agreement is in line with Akums’ Jain said, “This opens doors for us to
growth plans to expand in Europe and further expand our footprints in regula-
READY STOCK other regulated markets, alongside local in 2027 and will continue till 2032, the ted markets and replicate the domestic
company said. As part of this initiative, CDMO success globally.”
manufacturing.
Akums will initiate the European approval
ss 316 l As per the deal, estimated at €200-mn process for its oral liquid manufacturing Mr. Sandeep Jain, Managing Direc-
(Rs. 1,760-crore), Akums will produce facility. tor of Akums added, “These products are
currently being manufactured in Europe.
reacTOr and supply multiple stock keeping units of “The site and product dossier approvals Manufacturing these products in India
oral liquid formulations, which the partner
company will market across various Euro- are expected to be received by the end opens further collaboration opportunities
15 Kl & pean countries. of 2026,” Akums said, adding that it with other global pharma companies to
already operates two European-approved optimise their manufacturing costs and
6 Kl Commercial supply is expected to begin facilities for injectables and oral solids. make their supply chain robust”.
TREATING CANCER
Please Contact: Mankind Pharma and Innovent Biologics join up
Email: prakash@chemicalequipments.net
Mobile: 9819193438 / 00 for immunotherapy drug

Leading Importer & Stockist of Below Products Available MAnufACTuRERS / SuppliERS Of Mankind Pharma and China’s geal cancer, endometrial cancer and
AlCOhOl DEnATuRAnTS / biTTERAnTS
EX- Bhiwandi With Documentation & Technical Support S acetaldehyde Innovent Biologics have announced a Hodgkin’s lymphoma, the company
¾ GLYCINE ¾ L-LYSINE HCL S crotonaldehyde partnership to exclusively licence and added. Sintilimab injection is among
commercialise sintilimab, an advanced
the leading choices in immunotherapy,
¾ GUANIDINE HCL ¾ L-PHENYLALANINE S denatonium benzoate immunotherapy drug, in the Indian it said, benefi tting cancer patients since
S denatonium saccharide
¾ L-ALANINE ¾ L-PROLINE S pyridine base market. its launch in 2018.
¾ L-ARGININE BASE/HCL ¾ L-PYROGLUTAMIC ACID S caoutchoucine
The Lakshmiji Organics Pvt. Ltd.
¾ L-ASPARTIC ACID ¾ L-SERINE Sitapur, UP. Mob.: 09322661064 Sintilimab is marketed as Tyvyt (sin- Mankind Pharma will have exclu-
¾ L-CYSTEINE HCL MONOHYDRATE ¾ L-VALINE Email: organics@lakshmiji.com / loplstp@gmail.com tilimab injection) in China, a monoclonal sive rights to register, import, market,
¾ DISODIUM PHOSPHATE antibody co-developed by Innovent and sell and distribute sintilimab in India.
ANHYDROUS ¾ SODIUM PYRUVATE Anthranilic Acid Eli Lilly. “Its mechanism of blocking the Innovent will oversee manufacturing
¾ L-GLUTAMIC ACID ¾ TRIS BASE/HCL Isatoic Anhydride PD-1/PD-L1 pathway reactivates T-cells, and supply of the product, ensuring
¾ L-HYDROXYPROLINE ¾ URACIL 5 - Sulpho Anthranilic Acid enhancing the body’s natural ability to able effi cacy and favourable safety consistent availability and adherence
Phthalimide 99%
target and eliminate cancer cells,” a note across multiple major cancer types with to quality standards, it added. Innovent
RAIVAT IMPEX PRIVATE LIMITED Phenyl Hydrazine HCL from the company said. eight approved indications in China, will also be eligible to receive upfront,
Office No. 215, Sai Chamber, Near Bus Depot, Santacruz (East), Mumbai - 400055. Ishita Industries including non-small cell lung cancer, regulatory and commercial milestone
536, GIDC, Phase II, Vatva, Ahmedabad - 382 445.
Mob: 9820423514 / 8451810454 / 9136923514 Ph : +91 - 79 - 40083042 KNS ADI The drug has demonstrated remark- liver cancer, gastric cancer, oesopha- payments, it added.
Mobile : +91- 98250 60474 | +91- 99795 08254
Email: sales@navpad.in / info@navpad.in w Website: www.navpad.in (1) E-mail: info@ishitaind.com • Website: www.ishitaind.com
18/24
Chemical Weekly January 7, 2025 151

Contents Index to Advertisers Index to Products Advertised